Health Plans
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Novartis to Pay $422.5M to Settle Off-label Drug Marketing Charges

John Commins, for HealthLeaders Media, October 1, 2010

"Off-label marketing can undermine the doctor-patient relationship and adversely
influence the clear judgment that a doctor's patients have come to rely on and trust," said David Memeger, U.S. Attorney for the Eastern District of Pennsylvania, which led the federal probe.

"Pharmaceutical companies have a legal obligation to promote the drugs they manufacture only for uses that the FDA has deemed are safe and effective. That legal obligation takes priority over a company's bottom line."

In the civil agreement, Novartis will pay the federal government and participating states $237.5 million, plus interest, to settle invalid claims for payment for Trileptal and the other drugs that were submitted to Medicare, Medicaid, and other government-sponsored healthcare programs. State Medicaid programs will share $88.2 million of the settlement.

Novartis President for North America Andy Wyss said the U.S. subsidiary of Switzerland's Novartis International AG was "pleased" with the resolution. "(Novartis) will continue its commitment to high standards of ethical business conduct and regulatory compliance in the sale and marketing of our products," Wyss said. "Our goal is to ensure that patients receive the medicines they need and we will continue to work with the government and other organizations to improve healthcare for all Americans."

The civil cases were filed by former Novartis employees who will split $25.6 million from the settlement, under federal whistleblower statutes. Novartis also entered into a five-year corporate integrity agreement with Health and Human Services' Office of Inspector General.


John Commins is a senior editor with HealthLeaders Media.

Comments are moderated. Please be patient.

1 comments on "Novartis to Pay $422.5M to Settle Off-label Drug Marketing Charges"


taylor (5/11/2011 at 6:01 AM)
There's a lot of discussion about the state of medical care in the United States The doctor-patient partnership is heavily emphasized, for instance. For a while now, there has been a somewhat muffled undercurrent of doctors taking pharmaceutical business kickbacks to prescribe only certain medications to patients, and not always in the best interest of the patient. Accusations abound that the medical industry is rife with corruption. Taking out an <a title="Apply here for an installment loan" href="http://personalmoneystore.com/installment-loans/">installment loan</a> for prescription is probably not the best thing for you after-all.